PET developer Positron of Houston has acquired an exclusive license to a coronary disease reversal and prevention program developed by the University of Texas (UT) Health Science Center at Houston.
The program combines diagnostic assessment, pharmacologic and lifestyle management, and PET to advance preventive and clinical medicine. It is designed to identify the earliest stages of coronary disease before symptoms develop, as well as to determine when invasive procedures are unnecessary for coronary heart disease.
The program was created by Dr. K. Lance Gould, professor of cardiovascular medicine and executive director of the Weatherhead PET Center for Preventing and Reversing Atherosclerosis at the university.
Related Reading
Positron teams with Disease Management, June 25, 2008
Positron inks distributor deal with Utah firm, June 13, 2008
Positron buys Dose Shield, forms Positron Pharmaceuticals, June 13, 2008
Positron launches cardiac PET, October 17, 2007
Positron hires new VP, October 16, 2007
Copyright © 2008 AuntMinnie.com
